Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on developing gene circuit-engineered cell and gene therapies primarily targeting cancer. The company entered the public markets in 2022 through a business combination with Dynamics Special Purpose Corp., a blank-check vehicle in the healthcare and life sciences sector. On September 4, 2026, Senti Biosciences filed a DEFA14A—additional definitive proxy solicitation materials—with the U.S. Securities and Exchange Commission, signaling active shareholder communications tied to a pending corporate matter. The company remains listed on Nasdaq under the ticker SNTI. Visit SpacDesk to access the full filing history, shareholder vote timelines, and corporate event data for SNTI.